# pH-Thermo Dual-Responsive Polymeric Nanoparticles for Women’s Health: Dual Action Against Cervical and Ovarian Cancer Cells

**Authors:** Giuseppe Nunziata, Emanuele Limiti, Dania Aramini, Marco Nava, Luca Moretti, Alberto Rainer, Mattia Sponchioni, Filippo Rossi

PMC · DOI: 10.1021/acsami.5c18234 · 2025-10-28

## TL;DR

This paper introduces smart nanoparticles that respond to pH and temperature to deliver drugs more effectively to cervical and ovarian cancer cells.

## Contribution

The novelty lies in the dual-responsive polymeric nanoparticles combining pH and thermal sensitivity for targeted drug delivery in gynecological cancers.

## Key findings

- Nanoparticles showed sharp and reversible swelling/shrinking behavior in response to pH and temperature changes.
- Drug release was significantly enhanced under tumor-like acidic conditions and above the lower critical solution temperature.
- 5-fluorouracil delivered via nanoparticles showed increased therapeutic efficacy in cervical and ovarian cancer cells.

## Abstract

The development of
smart nanocarriers capable of responding to
tumor-specific stimuli represents a promising strategy for improving
therapeutic selectivity in oncology. In this work, we present a class
of dual-responsive polymeric nanoparticles (NPs) engineered for precision
drug delivery in gynecological cancers. Amphiphilic block copolymers
of the type P­(MAA)-b-P­(EG2MA-co-NIPAM) integrating pH-responsive methacrylic acid (MAA) and thermoresponsive
diethylene glycol methyl ether methacrylate (EG2MA) and N-isopropylacrylamide (NIPAM) units were synthesized via
reversible addition–fragmentation chain transfer (RAFT) polymerization.
Fine-tuning of the lower critical solution temperature (LCST) was
achieved by modulating the ratio between NIPAM and EG2MA,
yielding copolymers with cloud points within the physiologically relevant
range of 30–40 °C. The resulting NPs exhibited sharp and
reversible swelling/shrinking behavior in response to pH and temperature
stimuli, with sizes below 182 nm and narrow polydispersity indexes.
The core–shell architecture was stabilized by a dodecyl-functionalized
chain transfer agent, ensuring efficient self-assembly and robust
encapsulation of both hydrophilic and hydrophobic drugs. Drug release
studies with 5-fluorouracil (5-FU) and the drug-mimetic fluorescein
isothiocyanate (FITC) confirmed a marked temperature-triggered release
above the LCST and enhanced diffusion in mildly acidic conditions
(pH < 6), characteristic of solid tumors. Cellular studies on HeLa
and ovarian adenocarcinoma OVCA433 lines revealed rapid internalization,
high biocompatibility, and a significant increase in therapeutic efficacy
of 5-FU when delivered via NPs, compared to the free drug. These findings
highlight the potential of the dual-responsive nanoplatform for targeted
and controlled delivery in the treatment of cervical and ovarian cancers.

## Linked entities

- **Chemicals:** 5-fluorouracil (PubChem CID 3385)
- **Diseases:** cervical cancer (MONDO:0002974), ovarian cancer (MONDO:0005140)

## Full-text entities

- **Diseases:** Cervical and Ovarian Cancer (MESH:D010051), gynecological cancers (MESH:D009369)
- **Chemicals:** 5-FU (MESH:D005472), N-isopropylacrylamide (MESH:C067295), EG2MA (-), diethylene glycol methyl ether methacrylate (MESH:C000626809), P (MESH:D010758), MAA (MESH:C008384)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** OVCA433 — Homo sapiens (Human), Ovarian serous adenocarcinoma, Cancer cell line (CVCL_0475), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12616599/full.md

---
Source: https://tomesphere.com/paper/PMC12616599